For drug development purposes, a drug target smaller than 33 amino acids is desirable. Within the original MNTF 33mer sequence, Genervon further identified nine active sites and multiple drug targets. In vitro and in vivo experiments have confirmed that all identified targets have statistically similar biological effects with variations as the 33mer. Genervon discovered MNTF, a novel patented family of 9 human master regulators of the nervous system highly expressed during week 9 of embryonic development. These Master Regulators are potent disease modification drug candidates modulating many pathways including inflammation, apoptotic, hypoxia etc. GM600, one of the master regulators is the chosen drug candidate because its size was proven to be able to penetrate the crucial blood-brain barrier.
GM6 has all the advantages of a peptide-based drug: very high
potency and activity, low toxicity, minimum drug-to-drug interaction,
low accumulation in tissues (i.e., a short half-life), extremely high
specificity, and little to no unspecific binding to molecular
structures other than the desired targets. GM6 is small enough that it
does not have the disadvantages of large peptides in terms of
stability, solubility, mutagenicity, immunogenicity, or the high cost
of manufacturing through transgenic or recombinant methods.
Function to Pathways: 1,600 Genes Activated
Recent genomic, proteomic, and systems biology studies suggest that CNS
disorders and diseases implicate a highly complex, multi-factorial
process that involves the interplay of many non-dominant effectors in
an interwoven dynamic network. That expounds the futile efforts of
single action drugs.
MNTF is a specific, functional, regulatory, endogenous peptide
for the protection of the nervous system from disorders and diseases
including neurovascular and neurodegenerative diseases. Having
discovered MNTF by its function, Genervon used DNA micro-array analysis
to find the genes that are activated by its analogue GM6. That analysis
indicated that GM6 up or down regulates, by at least two fold, more
than 1,600 genes. Many of the modulated genes are related
to nervous system disorders and diseases, and neurodegenerative
diseases, including those in command of pathways for apoptosis,
oxidative stress, inflammation, lipid and immune response.
These analyses showed that GM6 activates genes involved in
neurogenesis, neural development, neuronal signaling plus many specific
biological functions. GM6 modulated significantly genes through many
GM6’s coordinated modulation of such a large number of
genes suggests a master-regulator that effects on this extremely intricate
network of disease-related pathways.